Research collaboration on a sub-class of epigenetic targets announced

Biotech company, Proteros, has entered into a new research collaboration with Janssen Biotech (one of the Janssen Pharmaceutical companies of Johnson & Johnson) that is aimed at discovering novel lead compounds against several epigenetic targets for various cancer indications.

Under the terms of the agreement, Janssen will gain access to Proteros’ proprietary Nucleosomal Epigenetic Assay Technology (NEAT) and discovery platform, which is aimed at technically complex targets. Additionally, Janssen can license the lead compounds for further development and commercialization or both companies can partner for further development.

“We are pleased to be working with Janssen to address a set of novel and complex epigenetic targets to create oncology drugs,” commented Dr Torsten Neuefeind, CEO of Proteros. “We believe that the structure of the collaboration will accelerate the discovery of novel therapies and maximize the value generation for both parties.”

Financial terms of the agreement were not disclosed.